RNF43 + GNAS
RNF43 and GNAS co-occurrence in pancreatic cancer (MSK-IMPACT 50K)
DataMSK-IMPACT 50K (2026) · Pancreatic cancer · 2,685 tumours · both altered in 8 (2.4 expected if independent)
This cohort pools pancreatic adenocarcinoma with pancreatic neuroendocrine tumours, so a pattern here can reflect the mix of tumour types rather than biology within one of them.
Weakened. Significant when all tumours are pooled, but not when tumours are compared only within the same tumour type or subtype: the effect fades rather than reverses.
A well-studied pair (385 papers): on the map it is known biology, a positive control rather than an overlooked discovery.
Signal (x) is the corrected significance on the map's scale. Efficacy (y) is credibility times actionability, the payoff if it is real.
These genes are altered together more often than chance would predict.
Pancreas
This finding's tumour type arises in the highlighted organ.
No structure profile is curated for this gene.
A human gene in this finding. Not in the curated driver set, so no structured profile is shown.
RNF43 mutations in pancreatic cancer →RNF43 co-mutations by tumour type →Other findings with RNF43 →No structure profile is curated for this gene.
A human gene in this finding. Not in the curated driver set, so no structured profile is shown.
GNAS mutations in pancreatic cancer →GNAS co-mutations by tumour type →Other findings with GNAS →Anatomical figure from the EBI Expression Atlas anatomogram, and predicted structures from the AlphaFold Protein Structure Database (both CC-BY-4.0). A model shows the protein's healthy fold; a highlighted residue marks a recurrent cancer position, not a prediction of a specific mutation's effect.
The raw 2×2 the FDR q and log₂ odds ratio above were computed from. It is the immutable evidence the score re-derives from: every number on this page traces back to these four counts.
| Gene state | RNF43 altered | RNF43 wild-type |
|---|---|---|
| GNAS altered | 8 | 54 |
| GNAS wild-type | 97 | 2,526 |
both 8 (expected 2.4 if independent) · GNAS-only 54 · RNF43-only 97 · neither 2,526
Weak evidence. Below the α=0.05 reject threshold (e≥20). Unlike a single-look p, this stays valid under the engine's continuous re-testing.
Molecular-subtype certification is unresolved. Recorded lineage only. Within-lineage molecular subtype remains unresolved. The association remains visible, but does not qualify as a subtype-controlled discovery.
The two axes are variables: signal (x) and efficacy (y = credibility × actionability). A point high on both lands in the frontier (top-right). A strong signal with low credibility sits low and to the right: statistically strong, not worth pursuing.
- Permalink
- https://cybergenic.im/findings/cee5f679-1b06-438a-8e04-0a753e81246e
- First seen
- 12 Aug 2026
- Prediction registry
- Locked 12 Aug 2026, row hash
6e10c471b1640893ec5771740c9bb16b(not testable out of sample). How the registry works
@misc{cybergenic_cee5f679,
author = {{Cybergenic}},
title = {{RNF43 and GNAS co-occurrence in pancreatic cancer (MSK-IMPACT 50K)}},
year = {2026},
howpublished = {\url{https://cybergenic.im/findings/cee5f679-1b06-438a-8e04-0a753e81246e}},
note = {Research engine finding, first seen 2026-08-12; prediction locked 2026-08-12, registry row hash 6e10c471b1640893ec5771740c9bb16b},
month = aug
}